Abstract
Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. This review evaluates the data from ongoing clinical and correlative studies of ibrutinib in B cell malignancies with a particular focus on CLL, and considers these data in the context of other B cell receptor pathway inhibitors.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adenine / analogs & derivatives
-
Agammaglobulinaemia Tyrosine Kinase
-
Disease-Free Survival
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Lymphoma, Mantle-Cell / drug therapy*
-
Piperidines
-
Protein Kinase Inhibitors / therapeutic use
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Protein-Tyrosine Kinases / metabolism
-
Pyrazoles / therapeutic use*
-
Pyrimidines / therapeutic use*
-
Receptors, Antigen, B-Cell / metabolism
-
Signal Transduction / drug effects
-
Waldenstrom Macroglobulinemia / drug therapy*
Substances
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyrimidines
-
Receptors, Antigen, B-Cell
-
ibrutinib
-
Protein-Tyrosine Kinases
-
Agammaglobulinaemia Tyrosine Kinase
-
BTK protein, human
-
Adenine